Baseline characteristics comparing patients with basilar artery occlusion and patients with large vessel occlusion in the anterior circulation
| Characteristics | BAO (n=165) | ACLVO (intracranial carotid artery, carotid-T, M1) (n=1574) | P value |
| Clinical items | |||
| Age (years) | 70 (59–80), N=165 | 73 (61–82), N=1574 | 0.019 |
| Transfer from another hospital | 80/165 (48.5%) | 561/1572 (35.7%) | 0.002 |
| Sex (female) | 69/165 (41.8%) | 810/1574 (51.5%) | 0.022 |
| NIHSS on admission | 18 (8–30), N=155 | 17 (12–20), N=1558 | 0.046 |
| Prestroke independence | 149/164 (90.9%) | 1446/1556 (92.9%) | 0.341 |
| Blood pressure systolic (mm Hg) | 148 (SD 31), N=86 | 150 (SD 28), N=1141 | 0.413 |
| Blood pressure diastolic (mm Hg) | 78 (SD 16), N=86 | 82 (SD 20), N=1139 | 0.097 |
| Admission glucose (mmol/L) | 7.5 (6.4–9.7), N=93 | 6.6 (5.8–8.1), N=1181 | <0.001 |
| Wake-up stroke | 13/161 (8.1%) | 123/1451 (8.5%) | 1.000 |
| TOAST etiology | 0.008 | ||
| Large artery | 37/163 (22.7%) | 205/1546 (13.3%) | |
| Cardioembolic | 64/163 (39.3%) | 733/1546 (47.4%) | |
| Other specific etiology | 12/163 (7.4%) | 101/1546 (6.5%) | |
| Unknown etiology | 50/163 (30.7%) | 507/1546 (32.8%) | |
| Medication | 0.058 | ||
| Antiplatelet | |||
| Monotherapy | 36/154 (23.4%) | 430/1463 (29.4%) | |
| Dual therapy | 0 (0%) | 26/1463 (1.8%) | |
| Statin | 32/142 (22.5%) | 395/1300 (30.4%) | 0.053 |
| Anticoagulation | 0.014 | ||
| VKA | 10/154 (6.5%) | 180/1464 (12.3%) | |
| NOAC | 2/154 (1.3%) | 64/1464 (4.4%) | |
| Risk factors | |||
| Diabetes | 23/163 (14.1%) | 271/1555 (17.4%) | 0.326 |
| Arterial hypertension | 87/163 (53.4%) | 1046/1553 (67.4%) | <0.001 |
| Dyslipidemia | 60/161 (37.3%) | 788/1547 (50.9%) | 0.001 |
| Smoking | 47/153 (30.7%) | 428/1499 (28.6%) | 0.574 |
| Previous stroke | 17/159 (10.7%) | 209/1565 (13.4%) | 0.389 |
| Coronary artery disease | 17/83 (20.5%) | 235/1131 (20.8%) | 1.000 |
| Type of imaging | 0.010 | ||
| MRI | 42/165 (25.5%) | 994/1544 (64.4%) | |
| CT | 123/165 (74.5%) | 550/1544 (35.6%) | |
| Treatment | |||
| IVT use | 71/165 (43.0%) | 779/1574 (49.5%) | 0.120 |
| Time from onset of symptoms to IVT needle (min) | 165 (113–210), N=39/71 | 120 (83–165), N=437/779 | 0.003 |
| Time from onset of symptoms to admission in stroke center (min) | 228 (IQR 121–369), N=132 | 143 (71–245), N=1380 | <0.001 |
| Time from onset of symptoms to groin puncture (min) | 300 (IQR 211–480), N=133 | 225 (165–315), N=1346 | <0.001 |
ACLVO, anterior circulation large-vessel occlusion; BAO, basilar artery occlusion; IVT, intravenous thrombolysis; NIHSS, National Institutes of Health Stroke Scale; NOAC, non-vitamin K antagonist oral anticoagulants;TOAST, Trial of ORG 10172 in Acute Stroke Treatment; VKA, vitamin K antagonist.Difference in numbers of observations and total numbers of patients in each group due to missing data items.